Standout Papers

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disea... 1997 2026 2006 2016 1.7k
  1. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease (1997)
    Mary Sano, Christopher Ernesto et al. New England Journal of Medicine
  2. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment (2005)
    Ronald Petersen, Ronald G. Thomas et al. New England Journal of Medicine
  3. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease (2014)
    Rachelle S. Doody, Ronald G. Thomas et al. New England Journal of Medicine
  4. A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease (2013)
    Rachelle S. Doody, Rema Raman et al. New England Journal of Medicine
  5. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. (2003)
    Paul Aisen, Kimberly Schafer et al. PubMed
  6. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. (2000)
    Ruth A. Mulnard, Carl W. Cotman et al. PubMed
  7. Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease (2010)
    Joseph F. Quinn, Rema Raman et al. JAMA
  8. Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change (1997)
    Lara Schneider, Jason T. Olin et al. Alzheimer Disease & Associated Disorders
  9. The Preclinical Alzheimer Cognitive Composite (2014)
    Michael Donohue, Reisa A. Sperling et al. JAMA Neurology
  10. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. (1988)
    Stephen G. Ellis, Gary S. Roubin et al. Circulation

Immediate Impact

1 by Nobel laureates 6 from Science/Nature 135 standout
Sub-graph 1 of 16

Citing Papers

Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
2023 Standout
Half a century of amyloids: past, present and future
2020 Standout
75 intermediate papers

Works of Ronald G. Thomas being referenced

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
2014 Standout
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
2008
and 19 more

Author Peers

Author Last Decade Papers Cites
Ronald G. Thomas 5459 7593 905 2923 175 18.2k
Gary W. Small 7069 9888 458 2140 241 20.3k
John C.S. Breitner 8961 7939 565 1919 270 20.2k
Gordon Wilcock 4197 5533 389 2538 223 14.3k
Patrizia Mecocci 4001 7505 276 1691 322 19.2k
Miia Kivipelto 9480 9864 920 1724 431 25.6k
Paul Aisen 7991 7982 1155 1727 269 16.4k
Francesco Panza 3512 6401 765 1486 364 14.6k
Rachelle S. Doody 9992 8341 1404 4213 240 20.7k
Michael Grundman 5786 6820 1037 2564 115 14.4k
Murray A. Raskind 5033 6577 399 2845 275 22.1k

All Works

Loading papers...

Rankless by CCL
2026